SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors

NCT07646626 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced (Unresectable) or Metastatic Solid Tumors

Interventions

DRUG: SSGJ-705
DRUG: SSGJ-612
DRUG: SSGJ-705 combined with chemotherapy

Sponsor

Shenyang Sunshine Pharmaceutical Co., LTD.